141 results on '"Kip, Michelle M A"'
Search Results
2. Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
3. Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study
4. Monitoring of rheumatoid arthritis: a patient survey on disease insight and possible added value of an innovative inflammation monitoring device
5. Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis
6. Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study
7. The societal impact of implementing an at-home blood sampling device for chronic care patients: patient preferences and cost impact
8. Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis.
9. Costs of Hospital‐Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System
10. Withdrawing biologics in non-systemic JIA:what matters to pediatric rheumatologists?
11. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands:a real-world data analysis
12. What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis?: A best-worst scaling survey
13. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
14. Preventing overuse of laboratory diagnostics: a case study into diagnosing anaemia in Dutch general practice
15. Understanding the adoption and use of point-of-care tests in Dutch general practices using multi-criteria decision analysis
16. Additional file 1 of Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
17. Additional file 2 of The societal impact of implementing an at-home blood sampling device for chronic care patients: patient preferences and cost impact
18. Additional file 4 of Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
19. Additional file 2 of Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
20. Additional file 8 of Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
21. Additional file 1 of The societal impact of implementing an at-home blood sampling device for chronic care patients: patient preferences and cost impact
22. Additional file 6 of Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
23. Additional file 7 of Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
24. Additional file 3 of Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
25. Additional file 5 of Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
26. Additional file 3 of The societal impact of implementing an at-home blood sampling device for chronic care patients: patient preferences and cost impact
27. Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review
28. Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands
29. Monitoring of rheumatoid arthritis: a patient survey on disease insight and possible added value of an innovative inflammation monitoring device
30. Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis
31. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
32. Additional file 1 of Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study
33. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis.
34. Health Economic Evaluation of a Strict Glucose Control Guideline Implemented Using Point-of-Care Testing in Three Intensive Care Units in The Netherlands
35. Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system
36. Costs of Hospital‐AssociatedCare for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System
37. Additional file 1 of Preventing overuse of laboratory diagnostics: a case study into diagnosing anaemia in Dutch general practice
38. Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system
39. Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?
40. Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system.
41. Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study.
42. Toward Alignment in the Reporting of Economic Evaluations of Diagnostic Tests and Biomarkers: The AGREEDT Checklist
43. Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients : results from a randomised controlled multicentre trial in the Netherlands
44. Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands
45. Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine
46. Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine
47. The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care
48. Assessing the cost-effectiveness of a routine versus an extensive laboratory work-up in the diagnosis of anaemia in Dutch general practice.
49. Procalcitonin to guide antibiotic stewardship in intensive care
50. Procalcitonin to guide antibiotic stewardship in intensive care
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.